TY - JOUR
T1 - Emerging translational science discoveries, clonal approaches, and treatment trends in chronic myeloproliferative neoplasms
AU - Mughal, Tariq I.
AU - Pemmaraju, Naveen
AU - Radich, Jerald P.
AU - Deininger, Michael W.
AU - Kucine, Nicole
AU - Kiladjian, Jean Jacques
AU - Bose, Prithviraj
AU - Gotlib, Jason
AU - Valent, Peter
AU - Chen, Chih Cheng
AU - Barbui, Tiziano
AU - Rampal, Raajit
AU - Verstovsek, Srdan
AU - Koschmieder, Steffen
AU - Saglio, Giuseppe
AU - Van Etten, Richard A.
N1 - Funding Information:
The 13th Post-ASH CML-MPN workshop comprised of C Abboud, O Abdel-Wahab, T Barbui, P Bose, T Brummerndorf, N Chatain, C Chen, J Crispino, M Deininger, S Elf, A Fleishmann, R Gale, J Gotlib, O Hantschel, R Hehlmann, C Jamieson, S Koschmieder, R Kralovics, R Levine G Martinelli, R Mesa, T Mughal, D Perrotti, T Odenike, H Gisslinger, Q Jiang, J Kiladjian, N Kucine, M Mauro, V Oehler, F Pane, N Pemmaraju, R Rampal, J Radich, G Saglio, R Scherber, T Shimoda, R Skoda, S Saussele, T Skorski, S Soverini, RA Van Etten, P Valent, S Verstovsek, and D Yan. The members wish to thank Alpa Parmar for her organizational skills, and Incyte Corporation, Novartis Oncology, Pharma Essentia, and Alpine Oncology Foundation for unrestricted grant support.
Funding Information:
The 13th Post‐ASH CML‐MPN workshop comprised of C Abboud, O Abdel‐Wahab, T Barbui, P Bose, T Brummerndorf, N Chatain, C Chen, J Crispino, M Deininger, S Elf, A Fleishmann, R Gale, J Gotlib, O Hantschel, R Hehlmann, C Jamieson, S Koschmieder, R Kralovics, R Levine G Martinelli, R Mesa, T Mughal, D Perrotti, T Odenike, H Gisslinger, Q Jiang, J Kiladjian, N Kucine, M Mauro, V Oehler, F Pane, N Pemmaraju, R Rampal, J Radich, G Saglio, R Scherber, T Shimoda, R Skoda, S Saussele, T Skorski, S Soverini, RA Van Etten, P Valent, S Verstovsek, and D Yan. The members wish to thank Alpa Parmar for her organizational skills, and Incyte Corporation, Novartis Oncology, Pharma Essentia, and Alpine Oncology Foundation for unrestricted grant support.
Funding Information:
Unrestricted educational grants from Incyte, Novartis, Pharma Essentia and Alpine Oncology Foundation
Publisher Copyright:
© 2019 John Wiley & Sons, Ltd.
PY - 2019/8
Y1 - 2019/8
N2 - The 60th American Society of Hematology (ASH) held in San Diego in December 2018 was followed by the 13th Post-ASH chronic myeloproliferative neoplasms (MPNs) workshop on December 4 and 5, 2018. This closed annual workshop, first introduced in 2006 by Goldman and Mughal, was organized in collaboration with Alpine Oncology Foundation and allowed experts in preclinical and clinical research in the chronic MPNs to discuss the current scenario, including relevant presentations at ASH, and address pivotal open questions that impact translational research and clinical management. This review is based on the presentations and deliberations at this workshop, and rather than provide a resume of the proceedings, we have selected some of the important translational science and treatment issues that require clarity. We discuss the experimental and observational evidence to support the intimate interaction between aging, inflammation, and clonal evolution of MPNs, the clinical impact of the unfolding mutational landscape on the emerging targets and treatment of MPNs, new methods to detect clonal heterogeneity, the challenges in managing childhood and adolescent MPN, and reflect on the treatment of systemic mastocytosis (SM) following the licensing of midostaurin.
AB - The 60th American Society of Hematology (ASH) held in San Diego in December 2018 was followed by the 13th Post-ASH chronic myeloproliferative neoplasms (MPNs) workshop on December 4 and 5, 2018. This closed annual workshop, first introduced in 2006 by Goldman and Mughal, was organized in collaboration with Alpine Oncology Foundation and allowed experts in preclinical and clinical research in the chronic MPNs to discuss the current scenario, including relevant presentations at ASH, and address pivotal open questions that impact translational research and clinical management. This review is based on the presentations and deliberations at this workshop, and rather than provide a resume of the proceedings, we have selected some of the important translational science and treatment issues that require clarity. We discuss the experimental and observational evidence to support the intimate interaction between aging, inflammation, and clonal evolution of MPNs, the clinical impact of the unfolding mutational landscape on the emerging targets and treatment of MPNs, new methods to detect clonal heterogeneity, the challenges in managing childhood and adolescent MPN, and reflect on the treatment of systemic mastocytosis (SM) following the licensing of midostaurin.
KW - IFNα
KW - MPNs
KW - clonal heterogeneity
KW - inflammaging
KW - investigational therapies
UR - http://www.scopus.com/inward/record.url?scp=85068135002&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85068135002&partnerID=8YFLogxK
U2 - 10.1002/hon.2622
DO - 10.1002/hon.2622
M3 - Review article
C2 - 31013548
AN - SCOPUS:85068135002
SN - 0278-0232
VL - 37
SP - 240
EP - 252
JO - Hematological Oncology
JF - Hematological Oncology
IS - 3
ER -